STOCK TITAN

Lemaitre Vasculr Stock Price, News & Analysis

LMAT Nasdaq

Welcome to our dedicated page for Lemaitre Vasculr news (Ticker: LMAT), a resource for investors and traders seeking the latest updates and insights on Lemaitre Vasculr stock.

LeMaitre Vascular (NASDAQ: LMAT) delivers innovative medical devices for vascular surgeons worldwide. This page provides centralized access to official announcements, financial disclosures, and strategic developments from the leader in peripheral vascular disease solutions.

Investors and medical professionals will find timely updates on product launches, regulatory milestones, and financial results. Track advancements in carotid shunts, vascular grafts, and other devices critical to open vascular surgery.

Our curated news collection enables you to monitor LMAT's progress in addressing circulatory challenges through cutting-edge technologies. Discover updates on manufacturing expansions, clinical study outcomes, and partnerships shaping the future of vascular care.

Bookmark this page for direct access to verified information about LeMaitre Vascular's surgical innovations and market leadership. Check regularly for new developments impacting the medical device sector and patient care standards.

Rhea-AI Summary

LeMaitre Vascular (Nasdaq:LMAT) announced its participation in two investor conferences this November. David Roberts, President, will present at the Stifel Virtual Healthcare Conference on November 16, 2020, at 8:00 AM ET. Meanwhile, JJ Pellegrino, Chief Financial Officer, is set to speak at the Canaccord Genuity 2020 Medical Technologies & Diagnostics Forum on November 19, 2020, at 9:30 AM ET. LeMaitre Vascular specializes in devices for treating peripheral vascular disease, serving over 200 million people globally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.32%
Tags
conferences
-
Rhea-AI Summary

LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced its Q3 2020 results with sales reaching $36.4 million, reflecting a 25% increase. Operating income surged 70% to $10.0 million, with a net income of $7.5 million, a 45% rise. The company declared a quarterly dividend of $0.095/share. Growth was driven by acquisitions and recovery in elective surgeries. However, gross margin fell to 62.3% from 69.3% a year prior. Guidance for Q4 anticipates sales between $34.0 million and $38.0 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.61%
Tags
-
Rhea-AI Summary

LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced it will release its third quarter 2020 financial results on October 29, 2020, after market close. A conference call is scheduled for 5:00 PM EDT that day to discuss the financial results and the company's outlook. Interested parties can join the call at 844-239-5284 or access the live webcast through their investor relations website.

LeMaitre Vascular specializes in devices for the treatment of peripheral vascular disease, a condition impacting over 200 million people globally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.36%
Tags
Rhea-AI Summary

LeMaitre Vascular (Nasdaq: LMAT) announced its participation in three investor conferences throughout September 2020. JJ Pellegrino, CFO, will engage in the Barrington Research Virtual Fall Investment Conference on September 9, followed by a presentation at the Cantor Virtual Global Healthcare Conference on September 15 at 4:00 PM EDT. Pellegrino will also present at the Sidoti Virtual Investor Conference on September 23 at 10:45 AM EDT. LeMaitre specializes in devices for treating peripheral vascular disease, impacting over 200 million globally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.86%
Tags
conferences
-
Rhea-AI Summary

LeMaitre Vascular, Inc. (Nasdaq: LMAT) announced participation in two upcoming investor conferences in August 2020. CFO JJ Pellegrino will present at the virtual Canaccord Genuity 40th Annual Growth Conference on August 13 at 8:00 AM EDT. Additionally, President David Roberts will attend the virtual 5th Annual Needham Med Tech & Diagnostics 1×1 Conference on August 17. LeMaitre Vascular specializes in devices and services for peripheral vascular disease, which affects over 200 million people globally, offering a diverse range of vascular devices for surgeons.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.06%
Tags
conferences
-
Rhea-AI Summary

LeMaitre Vascular, Inc. (LMAT) reported Q2 2020 results, with sales of $24.9 million, a decline of 16% year-over-year. Operating income fell 18% to $4.9 million, while net income decreased by 24% to $3.5 million, resulting in earnings of $0.17 per diluted share, down 25%. Despite a 20% operating margin, sales declined significantly due to the COVID-19 pandemic, particularly in the Americas and Europe. The company announced a quarterly dividend of $0.095 per share and provided limited Q3 guidance, projecting sales between $30.5 million and $34.5 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.3%
Tags
Rhea-AI Summary

LeMaitre Vascular, Inc. (Nasdaq: LMAT) will release its second quarter 2020 financial results on July 23, 2020, after market close. A conference call is scheduled for 5:00 PM EDT to discuss results, business highlights, and company outlook. LeMaitre offers devices and services for peripheral vascular disease, which affects over 200 million people globally. The company specializes in developing disposable and implantable vascular devices, targeting vascular surgeons with its diverse product portfolio.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.31%
Tags
-
News
Rhea-AI Summary

LeMaitre Vascular, Inc. (Nasdaq: LMAT) announced the acquisition of Artegraft, Inc. for $90 million, which includes $72.5 million in cash and potential earnouts of $17.5 million. Artegraft, known for its biologic vascular grafts used primarily in hemodialysis patients, generated $15.6 million in trade sales over the last year. This acquisition is expected to enhance LeMaitre's product offerings and profitability, positioning Artegraft as the largest product line in their sales portfolio. The deal will be funded through cash and a $65 million credit facility.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.3%
Tags
-
Rhea-AI Summary

LeMaitre Vascular, Inc. (Nasdaq: LMAT) announced that CFO JJ Pellegrino will speak at the Jefferies Virtual Healthcare Conference on June 4, 2020, at 2:00 PM EDT. LeMaitre Vascular specializes in developing and marketing devices for peripheral vascular disease, which impacts over 200 million individuals globally. The company offers a range of disposable and implantable vascular devices for use by vascular surgeons. More details can be found on their website at www.lemaitre.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.63%
Tags
conferences
Rhea-AI Summary

LeMaitre Vascular, listed on Nasdaq under the symbol LMAT, will be presented by President David Roberts at the UBS Virtual Global Healthcare Conference on May 20, 2020, at 8:20 AM EDT. The company specializes in developing and marketing devices for peripheral vascular disease, impacting over 200 million people globally. Their extensive product range focuses on disposable and implantable vascular devices tailored for vascular surgeons, enhancing treatment options for patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.53%
Tags
conferences

FAQ

What is the current stock price of Lemaitre Vasculr (LMAT)?

The current stock price of Lemaitre Vasculr (LMAT) is $84.75 as of May 21, 2025.

What is the market cap of Lemaitre Vasculr (LMAT)?

The market cap of Lemaitre Vasculr (LMAT) is approximately 1.9B.
Lemaitre Vasculr

Nasdaq:LMAT

LMAT Rankings

LMAT Stock Data

1.88B
20.60M
8.85%
95.59%
5.09%
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
Link
United States
BURLINGTON